Related Experiment Video
Updated: Jul 9, 2026
09:41
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Skin lesions induced by bortezomib
Ludek Pour1, Roman Hajek, Adam Zdenek
1Department of Internal Medicine-Hematooncology , Masaryk University Hospital, Jihlavska 20, Brno, 625 00, Czech Republic. lpour@fnbrno.cz
Haematologica
|February 9, 2006
Summary
Bortezomib therapy for multiple myeloma can cause a folliculitis-like rash. Prednisone effectively resolved and prevented this skin lesion, while antihistamines were ineffective.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Bortezomib is a proteasome inhibitor used in multiple myeloma treatment.
- Skin lesions are a known side effect of bortezomib therapy.
- Folliculitis-like rash is a specific dermatological manifestation observed.
Purpose of the Study:
- To describe six cases of bortezomib-induced skin lesions.
- To evaluate the efficacy of prednisone in managing these lesions.
- To determine preventative strategies for bortezomib-associated rash.
Main Methods:
- Case series reporting on six patients with relapsed multiple myeloma.
- Observation of skin lesion onset during bortezomib treatment cycles.
- Treatment intervention with prednisone and antihistamines.
Main Results:
- Folliculitis-like rash emerged during the second cycle of bortezomib.
- Prednisone administration resulted in rapid resolution of skin lesions.
- Prophylactic prednisone (10 mg) before bortezomib infusions prevented rash recurrence.
- Antihistamines alone did not prevent or resolve the rash.
Conclusions:
- Bortezomib can induce a distinct folliculitis-like skin rash in multiple myeloma patients.
- Prednisone is an effective treatment for bortezomib-induced skin lesions.
- Low-dose prednisone prophylaxis is crucial for preventing recurrent bortezomib-associated rash.
